Drug Price Transparency
Learn how Mark Cuban is disrupting drug pricing and making waves in the pharmaceutical industry. Find out more about his Cost Plus Drugs company and its collaborations with payers and pharmacists.
The CMS Innovation Center will test three new models to see whether they lower high drug costs, the Centers for Medicare & Medicaid Services announced yesterday.
AHA shares proposals to lower Medicare drug prices with congress.
The Purchaser Business Group on Health (PBGH), a coalition of about 40 large private and public employers including Walmart, Disney, Costco and Microsoft, recently launched EmsanaRx, a nonprofit PBM. Meanwhile, billionaire Mark Cuban’s Cost Plus Drug Company is another PBM that launched recently.
The Senate Judiciary Committee Subcommittee on Competition Policy, Antitrust, and Consumer Rights held a hearing on surging drug prices and anticompetitive conduct in the pharmaceutical industry.
The AHA July 2 expressed support for the Drug-Price Transparency for Consumers Act of 2021 (S.2304).
A new study demonstrates the cost to the U.S. health care system from an anti-competitive tactic known as “product hopping,” which involves a brand name drug company moving patients to a new reformulated version of a drug when an existing drug’s exclusivity is close to expiring.
The California Office of Statewide Health Planning and Development recently released the nation’s first mandatory data on wholesale acquisition cost increases for prescription drugs.
A recent report from UnitedHealth comparing specialty drug spending in hospitals and independent physician offices fails to account for critical differences between these two settings while also ignoring the chief culprit in the growth in drug spending – the drug companies themselves.
The House Energy and Commerce Committee today approved legislation to address surprise medical bills and Medicaid disproportionate share hospital cuts.